Veteran life-sciences investor and operating executive focused on commercialization and value-creation across biotech and medtech companies. Elizabeth Urish combines venture investing, corporate development and board experience to accelerate clinical-stage assets into strategic partnerships and exits. Background bridges scientific training and capital markets, with experience structuring licensing deals, syndicating rounds and advising management teams on go-to-market strategy. Regularly works with crossover investors and pharma corporates to de-risk programs and optimize capital allocation.
Veteran life-sciences investor and operating executive focused on commercialization and value-creation across biotech and medtech companies. Elizabeth Urish combines venture investing, corporate development and board experience to accelerate clinical-stage assets into strategic partnerships and exits. Background bridges scientific training and capital markets, with experience structuring licensing deals, syndicating rounds and advising management teams on go-to-market strategy. Regularly works with crossover investors and pharma corporates to de-risk programs and optimize capital allocation.
Focuses on late‑stage life‑sciences investments that bridge scientific validation and commercial exit, prioritizing clinical-stage biotech and medtech opportunities with clear de‑risking catalysts. Combines active board-level operational guidance with disciplined capital allocation, structuring licensing, syndication and pharma partnership pathways to shorten time horizon to strategic outcomes. Emphasizes clinical readouts, regulatory milestones and commercial fit as primary value drivers, maintains tight downside protection through staged financing, covenants and partner optioning while seeking asymmetric return profiles.
Focuses on late‑stage life‑sciences investments that bridge scientific validation and commercial exit, prioritizing clinical-stage biotech and medtech opportunities with clear de‑risking catalysts. Combines active board-level operational guidance with disciplined capital allocation, structuring licensing, syndication and pharma partnership pathways to shorten time horizon to strategic outcomes. Emphasizes clinical readouts, regulatory milestones and commercial fit as primary value drivers, maintains tight downside protection through staged financing, covenants and partner optioning while seeking asymmetric return profiles.
| Trades 583 | Longs Won 428/583 73% | Profit Factor 22.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $324,589.51 |
| Average Win $118,315.65 | Best Trade (Jul 15) $3.49M | Sharpe Ratio -11.37 |
| Average Loss -$14,439.55 | Worst Trade (Dec 31) -$300,824.18 | Z-Score 10.3 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 1w 2d | Expectancy $83,020.53 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 11,236 | 10,112 | 8,989 | 7,865 | 6,742 | 5,618 | 4,494 | 3,371 | 2,247 | 1,124 |